ATE529102T1 - Verbindung zur vorbeugung und behandlung von glaukoma - Google Patents

Verbindung zur vorbeugung und behandlung von glaukoma

Info

Publication number
ATE529102T1
ATE529102T1 AT04014078T AT04014078T ATE529102T1 AT E529102 T1 ATE529102 T1 AT E529102T1 AT 04014078 T AT04014078 T AT 04014078T AT 04014078 T AT04014078 T AT 04014078T AT E529102 T1 ATE529102 T1 AT E529102T1
Authority
AT
Austria
Prior art keywords
compound
glaucoma
prophylaxis
treatment
agent
Prior art date
Application number
AT04014078T
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE529102T1 publication Critical patent/ATE529102T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04014078T 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma ATE529102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28

Publications (1)

Publication Number Publication Date
ATE529102T1 true ATE529102T1 (de) 2011-11-15

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
AT99937073T ATE307609T1 (de) 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung
AT04014078T ATE529102T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
AT99937073T ATE307609T1 (de) 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung

Country Status (12)

Country Link
US (2) US6673812B1 (de)
EP (3) EP1459743B9 (de)
JP (2) JP3720264B2 (de)
KR (1) KR100616466B1 (de)
CN (2) CN1293878C (de)
AT (3) ATE527993T1 (de)
AU (1) AU5198199A (de)
CA (2) CA2635412C (de)
DE (1) DE69927936T2 (de)
ES (3) ES2374518T3 (de)
HK (3) HK1069121A1 (de)
WO (1) WO2000009162A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100396171B1 (ko) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
EP1163910B1 (de) * 1999-03-25 2007-09-26 Mitsubishi Pharma Corporation Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
EP1378247B1 (de) * 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Wirkstoffe zur behandlung von sehfunktionsstörungen
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
ATE546143T1 (de) * 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
ES2444841T3 (es) * 2002-11-18 2014-02-27 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (zh) * 2003-06-06 2008-05-28 旭化成制药株式会社 3环系化合物
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
WO2005079829A2 (en) * 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (fr) * 2004-04-02 2005-10-07 Oreal Utilisation cosmetique d'au moins un inhibiteur de la production et/ou de l'activation des rhoa kinases comme agent destine a detendre les traits et/ou decontracter la peau
ES2553953T3 (es) * 2004-06-03 2015-12-15 Senju Pharmaceutical Co., Ltd. Fármaco para la recuperación de la percepción corneal que contiene un compuesto amida
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
ZA200704959B (en) * 2004-12-27 2009-04-29 Alcon Inc Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
US20090029970A1 (en) * 2005-02-16 2009-01-29 Astellas Pharma Inc. Pain remedy containing rock inhibitor
WO2006137368A1 (ja) * 2005-06-21 2006-12-28 Kowa Co., Ltd. 緑内障の予防又は治療剤
PL1905452T3 (pl) * 2005-07-12 2013-11-29 Kowa Co Środek do zapobiegania lub leczenia jaskry
KR20080040027A (ko) 2005-09-02 2008-05-07 아스테라스 세이야쿠 가부시키가이샤 Ｒｏｃｋ 억제제로서 아미드 유도체
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP1962853A1 (de) * 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazine und (1,3-dihydro-indol-2-on)-pyrazine zur behandlung rho-kinase-vermittelter erkrankungen und leiden
EP2025676A4 (de) 2006-06-08 2011-06-15 Ube Industries Neues indazolderivat mit spiroringstruktur in der seitenkette
US20090247552A1 (en) * 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
CA2674548A1 (en) 2006-12-26 2008-07-03 Santen Pharmaceutical Co., Ltd. Novel n-(2-aminophenyl) benzamide derivative having urea structure
KR20090125209A (ko) 2007-03-28 2009-12-03 산텐 세이야꾸 가부시키가이샤 히스톤 탈아세틸화 효소 저해 작용을 갖는 화합물을 유효 성분으로서 함유하는 안압 하강제
US8012972B2 (en) 2007-03-28 2011-09-06 Santen Pharmaceutical Co., Ltd. Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR20100080514A (ko) 2007-08-29 2010-07-08 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
US8372811B2 (en) * 2007-09-21 2013-02-12 Eyegene, Inc. Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
KR20110028262A (ko) 2008-05-23 2011-03-17 산텐 세이야꾸 가부시키가이샤 우레아 구조를 갖는 신규 티오펜디아민 유도체
EP2319539A4 (de) * 2008-07-24 2012-03-28 Univ Osaka Prophylaktischer oder therapeutischer wirkstoff gegen axiale myopie
EP2319514A4 (de) * 2008-07-25 2011-11-02 Asahi Kasei Pharma Corp Stabile wässrige lösungszusammensetzung mit einer sulfonamidverbindung
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010032875A2 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
AR078033A1 (es) 2009-04-03 2011-10-12 Plexxikon Inc Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9693899B2 (en) 2009-07-09 2017-07-04 Ivantis, Inc. Single operator device for delivering an ocular implant
CA2766192C (en) 2009-07-09 2017-10-24 Ivantis, Inc. Ocular implants for residing partially in schlemm's canal
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012015760A1 (en) * 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
EP2671586B1 (de) 2011-02-04 2018-05-30 Kowa Co., Ltd. Medikamentöse therapie zur prävention oder behandlung von glaukomen
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CA2878370C (en) * 2012-07-13 2021-01-19 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
EP3626245B1 (de) 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutikum für erkrankungen des augenhintergrunds
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
US11197779B2 (en) 2015-08-14 2021-12-14 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
WO2017106517A1 (en) * 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
TWI788484B (zh) 2017-12-21 2023-01-01 日商參天製藥股份有限公司 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
WO2021156275A1 (en) 2020-02-05 2021-08-12 Nicox S.A. Compositions for the treatment of glaucoma and ocular hypertension
EP4274529A1 (de) 2021-01-11 2023-11-15 Alcon Inc. Systeme und verfahren zur viskoelastischen freisetzung
KR20230157307A (ko) 2021-01-11 2023-11-16 인사이트 코포레이션 Jak 경로 억제제 및 rock 억제제를 포함하는 병용 요법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
DE69231297T2 (de) * 1991-09-06 2000-11-23 Yoshitomi Pharmaceutical 4-amino(alkyl)cyclohexan-1-carboxamidverbindungen und ihre verwendung
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH07133225A (ja) 1993-11-09 1995-05-23 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
EP1195372A1 (de) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
JPH09143099A (ja) 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
KR100452715B1 (ko) * 1995-12-21 2004-12-17 알콘 래보레이토리스, 인코퍼레이티드 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
US6218410B1 (en) * 1996-08-12 2001-04-17 Yoshitomi Pharmaceutical Industries, Ltd. Medicines comprising Rho kinase inhibitor

Also Published As

Publication number Publication date
EP1034793B1 (de) 2005-10-26
ATE307609T1 (de) 2005-11-15
EP1459742A3 (de) 2007-12-26
KR20010015761A (ko) 2001-02-26
CN1195547C (zh) 2005-04-06
EP1459742A2 (de) 2004-09-22
CN1293878C (zh) 2007-01-10
ATE527993T1 (de) 2011-10-15
EP1459743A3 (de) 2007-12-26
US6673812B1 (en) 2004-01-06
CN1287494A (zh) 2001-03-14
JP2004277432A (ja) 2004-10-07
CA2635412C (en) 2011-06-21
CA2307285C (en) 2009-03-31
EP1459743B9 (de) 2012-08-01
EP1459743A2 (de) 2004-09-22
CA2635412A1 (en) 2000-02-24
HK1030883A1 (en) 2001-05-25
WO2000009162A1 (fr) 2000-02-24
CA2307285A1 (en) 2000-02-24
EP1459742B9 (de) 2012-05-02
ES2374518T3 (es) 2012-02-17
HK1069120A1 (en) 2005-05-13
EP1034793A4 (de) 2003-07-09
EP1459743A8 (de) 2005-02-02
DE69927936T2 (de) 2006-06-29
KR100616466B1 (ko) 2006-08-29
ES2372572T3 (es) 2012-01-23
AU5198199A (en) 2000-03-06
HK1069121A1 (en) 2005-05-13
ES2247822T3 (es) 2006-03-01
EP1459743B1 (de) 2011-10-19
DE69927936D1 (de) 2005-12-01
EP1459742B1 (de) 2011-10-12
JP3720264B2 (ja) 2005-11-24
JP4490748B2 (ja) 2010-06-30
CN1494903A (zh) 2004-05-12
US20030125351A1 (en) 2003-07-03
US6649625B2 (en) 2003-11-18
EP1034793A1 (de) 2000-09-13

Similar Documents

Publication Publication Date Title
ATE529102T1 (de) Verbindung zur vorbeugung und behandlung von glaukoma
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
CY1108651T1 (el) Προληπτικος ή θεραπευτικος παραγων για γλαυκωμα
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
DE60036540D1 (de) Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
DE69019774T2 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
PT1263504E (pt) Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa
DE69907418T2 (de) Verwendung von makroliden zur behandlung von glaukom
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
MXPA03012039A (es) Derivados de benzo [g]quinolina para tratar glaucoma y miopia.
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE10080190D2 (de) Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs
WO2001035948A3 (en) Neurophilin ligands for treating ocular conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties